Tuberc Respir Dis.  2011 May;70(5):384-389.

Issues on Safety of Long-Acting Muscarinic Antagonist

• Lee YD
• Cho Y
• Han MS

Abstract

The prevention of and the controlling of symptoms, reductions in the frequency of exacerbations, and disease severity are central to the pharmacologic therapy of chronic obstructive pulmonary disease (COPD). COPD patients are inclined to be older, have more comorbidities, and use polypharmacy as a result. Long-acting inhaled muscarinic antagonists (LAMAs) is a preferred treatment modality. However, the cardiovascular (CV) safety of anti-cholinergics, including LAMA, has been an issue. In contrast, the results of the UPLIFT trial and a pooled analysis of data from 30 trials of tiotropium illustrates the association of tiotropium with reductions in the risk of all cause mortality, CV mortality and CV events. And, the UPLIFT trial provides clues regarding the additive advantages of tiotropium in COPD patients who already are using long-acting inhaled beta2 agonists and inhaled corticosteroids. Following the contribution of tiotropium as a first LAMA, new LAMAs such as aclidinium and glycopyrrolate (NVA-237) seem to be emerging.

Keyword

Pulmonary disease, Chronic Obstructive; Cholinergic Antagonists; tiotropium; Muscarinic Antagonists

MeSH Terms

Adrenal Cortex Hormones
Cholinergic Antagonists
Comorbidity
Glycopyrrolate
Humans
Muscarinic Antagonists
Polypharmacy
Pulmonary Disease, Chronic Obstructive
Scopolamine Derivatives
Tiotropium Bromide
Adrenal Cortex Hormones
Cholinergic Antagonists
Glycopyrrolate
Muscarinic Antagonists
Scopolamine Derivatives

Reference

1. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, updated 2010 [Internet]. c2010. cited 2011 May 13. Bethesda, MD: GOLD;Available from: http://www.goldcopd.com/download.asp?intId=617.

2. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med. 2010. 16:97–105.

3. Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2010. 19:257–264.

4. Kim SJ, Kim MS, Lee SH, Kim YK, Moon HS, Park SH, et al. A comparison of tiotropium 18 microgram, once daily and ipratropium 40 microgram, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease. Tuberc Respir Dis. 2005. 58:498–506.

5. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis [Internet]. 2008. Cited 2011 May 13. Silver Spring, MD: US Food and Drug Administration;Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf.

6. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008. 149:380–390.

7. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008. 300:1439–1450.

8. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008. 359:1543–1554.

9. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010. 137:20–30.

10. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium--the FDA's conclusions. N Engl J Med. 2010. 363:1097–1099.

11. Barnes PJ. The pharmacological properties of tiotropium. Chest. 2000. 117:2 Suppl. 63S–66S.

12. Valente S, Pasciuto G, Bernabei R, Corbo GM. Do we need different treatments for very elderly COPD patients? Respiration. 2010. 80:357–368.

13. Spiriva Handihaler package insert. 2010. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc..

14. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006. 130:1695–1703.

15. Pedone C, Incalzi RA. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2009. 360:185.

16. Chang ET. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2009. 360:185.

17. O'Connor AB. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2009. 360:185–186.

18. Singh S, Furberg CD, Loke YK. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2009. 360:186.

19. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2009. 169:1403–1410.

20. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005. 18:273–282.

21. Caillaud D, Le Merre C, Martinat Y, Aguilaniu B, Pavia D. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007. 2:559–565.

22. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009. 330:660–668.

23. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest. 2005. 128:1974–1979.

24. Sato E, Koyama S, Okubo Y, Kubo K, Sekiguchi M. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol. 1998. 274:L970–L979.